Acadia and Anovo Partner to Transform Rett Syndrome Care
October 3, 2023
Acadia Pharmaceuticals, Inc. is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for central nervous system (CNS) disorders. With a focus on discovering, developing, and commercializing small molecule drugs, Acadia tackles some of the most challenging issues in neuroscience to provide innovative solutions to individuals in need.
What is Rett Syndrome?
Rett Syndrome is a rare and severe neurological disorder that predominantly affects females. Characterized by developmental regression, loss of speech and hand use, repetitive hand movements, seizures, and breathing irregularities, Rett Syndrome profoundly impacts the lives of affected individuals and their families. Despite its rarity, Rett Syndrome poses significant challenges, highlighting the urgent need for effective treatments to alleviate symptoms and improve quality of life.
Acadia Pharmaceuticals, Inc. Partners with Anovo
Our collaboration with Acadia Pharmaceuticals, Inc. represents a significant milestone in addressing the complexities of Rett Syndrome and providing support to individuals and families affected by this condition. We’re proud to provide crucial patient services through Acadia Connect. This platform ensures seamless access to DAYBUE™ (trofinetide), Acadia’s groundbreaking treatment for Rett syndrome.
As the exclusive distributor and specialty pharmacy for DAYBUE, we’re also uniquely positioned to deliver care and support tailored to the needs of patients and their caregivers. Together with Acadia Pharmaceuticals, Inc., we are dedicated to making a meaningful difference in the lives of individuals affected by Rett Syndrome.
Related Posts
How Anovo Builds Dedicated Teams to Support Your Rare Disease Therapy
At Anovo, we understand that complex rare disease therapies require high-touch service that large payer- and Pharmacy Benefit Manager-owned Specialty…
January 30, 2025
Justin’s Story: Living with Duchenne Muscular Dystrophy
When Justin was first diagnosed with Duchenne muscular dystrophy, his parents, Amanda and Andrew, weren’t sure how to navigate the…
January 14, 2025
Eton Pharmaceuticals & Anovo Partner to Expand Access for Patients with Severe Primary Insulin-Like Growth Factor 1 Deficiency
Eton Pharmaceuticals is dedicated to developing and commercializing treatments for rare diseases, with a strong focus on pediatric endocrinology. Their…
December 20, 2024
